Gland Pharma Ltd.

“Gland Pharma's operational competence in sterile injectables cannot offset the compounding negatives: ROCE collapsed from 25%+ to sub-10%, incremental capital deployment is value-destructive, Fosun's ~58% controlling stake creates structural misalignment with minority shareholders and an existential geopolitical conflict with its US revenue base, and the stock at 34.5x trailing earnings offers no margin of safety against any of these risks materializing further. The 10-year expected return is at best 1.5–2x — index-lagging returns with governance and regulatory risk that is non-trivial and non-temporary.”